Continued research and development activities
First written in FY2022-Q2. 8 of 12 entries say "Restated". Latest entry: FY2026.
54 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Based on its Medium-Term Management Plan 2027, the Group undertook a fundamental review of its research and development structure, strengthened collaboration with each business, consolidated knowledge across domains and established an R&D organization designed to accelerate development and create innovation.」
The company progressed from continuing its conventional research and development activities to building a cross-domain R&D organization. Research and development expenses were ¥10,914 million, with priority allocation to the diagnostics and life sciences areas continuing. - FY2026-H1RestatedAnnual report
「The total research and development expenses of the Group for the interim consolidated accounting period were ¥5,344 million. There were no material changes in the Group's research and development activities during the interim consolidated accounting period.」
The company stated that there had been no material changes in its research and development activities and recorded research and development expenses of ¥5,344 million for the interim period. - FY2025AdvancedAnnual report
「The company is positioning the diagnostics and life sciences areas as priority fields expected to deliver high growth and is concentrating management resources on them.」
The company recorded research and development expenses of ¥10,727 million and is concentrating research and development resources on digital pathology, cellular metabolism monitoring, CGT and other areas, with diagnostics and life sciences designated as priority fields. - FY2024AdvancedAnnual report
「The Group's research and development expenses were ¥11,971 million.」
Research and development expenses increased from ¥10,391 million in the previous year. The company is prioritizing growth areas and advancing development of cloud-based electronic medical records, next-generation CGM models, digital pathology and cellular metabolism monitoring. - FY2024-Q3RestatedAnnual report
「The total research and development expenses of the Group for the nine months ended [current third quarter] were ¥8,553 million. There were no material changes in the Group's research and development activities during the nine months ended [current third quarter].」
The company recorded research and development expenses of ¥8,553 million and states that there have been no material changes in its research and development activities. - FY2024-Q2RestatedAnnual report
「The total amount of the Group's research and development activities during the six-month period ended the second quarter was ¥5,368 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
The company recorded research and development expenses of ¥5,368 million and states that there have been no material changes in its research and development activities. - FY2024-Q1RestatedAnnual report
「The total amount of the Group's research and development activities during the three-month period ended the first quarter was ¥2,687 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
Recorded research and development expenses of ¥2,687 million and stated that there were no material changes in the status of research and development activities. - FY2023-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the nine-month period ended the third quarter was ¥7,601 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
Recorded research and development expenses of ¥7,601 million and stated that there were no material changes in the status of research and development activities. - FY2023-Q2RestatedAnnual report
「The total amount of the Group's research and development activities during the six-month period ended the second quarter was ¥4,965 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
Recorded research and development expenses of ¥4,965 million and stated that there were no material changes in the status of research and development activities. - FY2023-Q1RestatedAnnual report
「The total amount of the Group's research and development activities during the three-month period ended the first quarter was ¥2,477 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
Recorded research and development expenses of ¥2,477 million and stated that there were no material changes in the status of research and development activities. - FY2022-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the nine-month period ended the third quarter was ¥7,690 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
Recorded research and development expenses of ¥7,690 million and stated that there were no material changes in the status of research and development activities. - FY2022-Q2First statedAnnual report
「The total amount of the Group's research and development activities during the six-month period ended the second quarter was ¥5,144 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
Recorded research and development expenses of ¥5,144 million and stated that there were no material changes in research and development activities.